Tenon Medical, Inc.

TNON

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001560293

None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $10.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	6 of 13
Graded from	filings received through Mar 27, 2026 240 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026
Last close	$0.90 2026-11-20; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Medical, Inc. ("we" or the "Company") was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. We are a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. We currently offer two systems to treat a diseased sacroiliac joint (the "SI Joint"). We have developed The Catamaran®? SI Joint Fusion System ("The Catamaran System") that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. We received U.S.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 42.7						
Gross profitability	21.9%	32.8%		61.7	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(17.6%)	(6.7%)		23.6	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 4						
Solvency, sleeve percentile 76.5						
Altman Z double-prime	(29.53)	0.31		81.4	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
interest expense must exceed $100,000						
Current ratio	2.11x	2.68x		71.7	781	2025-12-31
Growth and financing, sleeve percentile 30.4						
Revenue growth, three-year compound	78.7%	9.6%		7.0	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	(1.0%)	3.2%		53.8	663	2025-12-31
Net share issuance, one year	not computable	1.6%				
firm-wide XBRL shares cannot be assigned to one ticker class						

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(90.3%)	(1.7%)	3
Distance from 52-week high	(97.8%)	(33.0%)	2
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	not computable	0.29	
Sales to price	not computable	0.38	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(2.50)	(0.19)	3
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$8.3M
Operating cash flow, four quarters	-$10.3M
Months of runway	9.6
Days since last periodic filing	6 (10-Q received Nov 16, 2026)
Median daily dollar volume, 63 sessions	$567,189

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.4M	2025-12-31	2026-03-27	10-K	26-035707
2	assets	us-gaap:Assets	$10.8M	2025-12-31	2026-03-27	10-K	26-035707
3	net income	us-gaap:NetIncomeLoss	-$12.6M	2025-12-31	2026-03-27	10-K	26-035707
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.7M	2025-12-31	2026-03-27	10-K	26-035707
5	assets	us-gaap:Assets	$9.8M	2024-12-31	2026-03-27	10-K	26-035707
6	current assets	us-gaap:AssetsCurrent	$6.8M	2025-12-31	2026-03-27	10-K	26-035707
7	current liabilities	us-gaap:LiabilitiesCurrent	$3.2M	2025-12-31	2026-03-27	10-K	26-035707
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$81.3M	2025-12-31	2026-03-27	10-K	26-035707
9	operating income	us-gaap:OperatingIncomeLoss	-$12.8M	2025-12-31	2026-03-27	10-K	26-035707
10	book equity	us-gaap:StockholdersEquity	$5.0M	2025-12-31	2026-03-27	10-K	26-035707
11	liabilities	us-gaap:Liabilities	$5.7M	2025-12-31	2026-03-27	10-K	26-035707
12	operating income	us-gaap:OperatingIncomeLoss	-$15.7M	2023-12-31	2025-03-26	10-K	25-002734
13	interest expense	us-gaap:InterestExpense	$21,000	2023-12-31	2024-03-29	10-K	24-028010
14	revenue	us-gaap:Revenues	$3.9M	2025-12-31	2026-03-27	10-K	26-035707
15	revenue	us-gaap:Revenues	$3.3M	2024-12-31	2026-03-27	10-K	26-035707
16	revenue	us-gaap:Revenues	$2.9M	2023-12-31	2025-03-26	10-K	25-002734
17	revenue	us-gaap:Revenues	$691,000	2022-12-31	2024-03-29	10-K	24-028010
18	assets	us-gaap:Assets	$6.3M	2023-12-31	2025-03-26	10-K	25-002734
19	assets	us-gaap:Assets	$11.1M	2022-12-31	2024-03-29	10-K	24-028010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.